Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6332352 | 0.91 | CCKBR (0.59) | CCKBR | |
| SCHEMBL6330226 | 0.81 | CCKBR (0.49) | CCKBRSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL6330236 | 0.80 | CCKBR (0.49) | CCKBRSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL7985183 | 0.80 | CCKBR (0.46) | CCKBR | |
| SCHEMBL7083603 | 0.77 | CCKBR (0.81) | CCKBRRAB9A | |
| SCHEMBL6096321 | 0.77 | CCKBR (0.61) | CCKBRFKBP1A | |
| SCHEMBL6334312 | 0.76 | CCKBR (0.49) | CCKBRSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL6332182 | 0.74 | CCKBR (0.60) | CCKBRRAB9AFKBP1A | |
| SCHEMBL6332186 | 0.74 | CCKBR (0.60) | CCKBRRAB9AFKBP1A | |
| SCHEMBL6332183 | 0.74 | CCKBR (0.60) | CCKBRSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878734-B2 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | GRPR, CCKBR, GIPR | CCKBR 2/4885SMN1; SMN2 4720/4885NPC1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.